Eli Lilly bets on Alzheimer's disease drug data as it chases Biogen
The Peninsula
Eli Lilly and Co said on Tuesday it plans to seek U.S. approval for its experimental Alzheimer's disease drug by year end and believes the treatment could be favored by doctors once it becomes available to patients.
Eli Lilly shares were up 4% A landmark U.S. approval of Biogen Inc's Alzheimer's drug in June has boosted the chances for other medicines that clear plaques from the brain. Several companies including Lilly have been hoping to bring similar drugs to market.More Related News